Evolution Of Pain In Patients With Metastatic Pancreatic Carcinoma Treated With Folfirinox Or Gemcitabine In A Randomized Phase Iii Study (Accord11/Prodige4).

e15251 Background: Efficacy of FOLFIRINOX regimen versus Gemcitabine (gem) as first-line therapy among patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) has already been reported (NEJM, 2011; 364:1817-25). An analysis of EORTC Quality of Life (QoL) Questionnaire QLQ-C30 based on a time to definitive deterioration approach (TUDD) confirmed that FOLFIRINOX significantly reduces QoL impairment compared with gem in patients with mPAC. The present exploratory analysis aims to provide some additional insight about the impact of FOLFIRINOX on pain evolution. Methods: Baseline pain scores measured withQLQ-C30 were available for a total of 333/342 pts from the ACCORD11/PRODIGE4 trial (167 and 166 pts in FOLFIRINOX groupand Gem group respectively). The considered endpoint was pain intensity as perceived by the pt according to QLQ-C30 scale and the analgesic consumption at baseline and during treatment. A Linear Mixed Model was used to assess pain score evolution. Results: Baseline QLQ-C30 pain scores ...